US 340B Discount Restrictions By Pharma: HRSA Will Continue To ‘Walk The Walk’ In Opposition
Executive Summary
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
You may also be interested in...
340B Court Ruling Offers Manufacturers Short-Term Reprieve In Contract Pharmacy Dispute
Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.
340B Contract Pharmacy Feud: Court Undercuts HHS Position Against Drug Firms In Ruling
Federal district court denies HHS request to dismiss AstraZeneca’s lawsuit, but also suggests Congress needs to clarify the contract pharmacy issue.
340B Hospitals Could See Audits On Use Of Drug Price Savings Under Biden Administration Proposal
Legislation would be needed and will be complicated to develop. While the effectiveness of existing audits has been question by a federal government watchdog, the proposal in Biden’s budget document suggests the administration has some sympathy with drug sponsors’ position in the ongoing fight over the 340B drug discount program.